TRANSGENE (ENX:TNG) Announces Management Changes

TRANSGENE (ENX:TNG) Announces Management Changes

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News : Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) announced today the further strengthening of its management team following the recent arrival of Eric Quémeneur as Executive Vice President, Vice President Research & Development. The management committee of Transgene, chaired by Philippe Archinard, Chairman and Chief Executive Officer, is now composed of: Eric Quémeneur; Dr Nathalie Adda, Vice President, Chief Medical Officer; Christophe Ancel, Vice President Quality and Qualified Person; Jean-Philippe Del, Vice President Finance; Thibaut du Fayet, Vice President Alliance Management, Project Management and Marketing; Colin Freund, Vice President Business Development; Patrick Mahieux, Vice President Industrial and Pharmaceutical Operations; and Hemanshu Shah, Vice President Medical Affairs. Stéphane Boissel, Executive Vice President and Chief Financial Officer, announced that he is leaving the Company to pursue other opportunities.

Suggested Articles

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.

Seven years after regaining the fibrosis drug it had licensed out to Stromedix, Biogen is pulling the plug on a phase 2 study.